Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Bad Reviews For Merck's Proscar


In Business This Week

BAD REVIEWS FOR MERCK'S PROSCAR

Prospects for Merck's prostate-shrinking drug, Proscar, may be shrinking. The drug, used to treat enlarged prostates, is often less effective and more costly than surgery, according to a urologist's editorial in the Oct. 22 New England Journal of Medicine.

The editorial was based on data contained in the journal's cover article, in which Merck scientists reported on the successful results of their clinical trials of the drug. Dr. Paul Lange of the University of Washington, who was cited in a BUSINESS WEEK article last July questioning the drug's effectiveness, remains unconvinced. He also warned that using Proscar can hamper prostate-cancer detection.

In any case, prescriptions for Proscar are running below expectations. Consultant Hemant Shah now expects annual Proscar sales to peak at $500 million by the late 1990s. New prescriptions in September totaled 26,000, up just 4,000 from August, and a fraction of what analysts had at first expected.EDITED BY DEIDRE A. DEPKE


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus